Post-treatment lifestyle choices influence long-term outcomes in breast cancer patients

Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA – Psychedelic Alpha

Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome VANCOUVER, BC, Aug. 31, 2023 /CNW/ –

August 31, 2023

Long COVID linked to higher risk of erectile dysfunction, new study finds

The risk of developing erectile dysfunction (ED) following a diagnosis of long coronavirus disease (COVID) compared to acute COVID.

June 4, 2024

Antibiotic activity altered by interaction with nanoplastics, new research shows

Nanoplastics significantly alter antibiotic interactions, reducing effectiveness and increasing resistance, posing serious implications for health and ecology.

November 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.